Linked media – Related media
The drug that is revolutionizing the treatment of obesity, semaglutida (wegovy), expands its health benefits and, according to the FLOW study (Evaluation of renal function with semaglutida once a week) published in “The New England Journal of Medicines” (NEJM), this drug also significantly reduces the risk of renal failure, cardiovascular arrest, and mortality in patients with type 2 diabetes and chronic renal failure.
The speech, presented at the 61st ERA Congress, will pave the way towards new treatment strategies and offer hope to millions of patients around the world.
The FLOW study is an international, random, placebo-controlled, double-sky trial that includes 3,533 patientswith an average follow-up period of 3.4 years.
The trial was designed to evaluate the efficacy and safety of semaglutide, administered once weekly subcutaneously, for the prevention of serious renal outcomes, particularly renal failure, substantial loss of renal function, and death from renal or cardiovascular causes , in individuals with type 2 diabetes and chronic renal failure. Patients received semaglutida 1.0 mg once weekly or placebo.
The results show that those treated with semaglutida had a 24% risk reduction on the main evaluation criterion that included renal outcomes and deaths from cardiovascular and renal causes, compared to those who received placebo. This risk reduction was consistent with kidney-specific outcomes, such as cardiovascular death.
Less deadly
The therapy also has full beneficial effects in other aspects, such as the risk of cardiovascular events and the risk of all-cause mortality.
Vlado Perkovic, who presented the results, underlined the importance of these results: «The use of semaglutida in people with type 2 diabetes and chronic kidney disease can reduce the risk of serious kidney problems and cardiovascular events, cardiovascular death and death of all causes. These -added- benefits imply a profound clinical impact, saving hearts, hearts and lives for patients with type 2 diabetes and chronic kidney disease. Furthermore, the hallazgos de seguridad tranquiladores highlight even more the great potential value of semaglutide in this population.”
Chronic kidney disease affects over 800 million people worldwide and is prevalent in type 2 diabetes
Chronic kidney disease affects more than 800 million people worldwide and is particularly prevalent among individuals with type 2 diabetes. Additionally, it poses a significant risk of kidney failure, cardiovascular events, and death. And, although current therapies have been shown to protect rivers and reduce cardiovascular risks, many individuals continue to experience deterioration in kidney function and adverse outcomes. This has generated a creative interest in exploring new treatments, including GLP-1.1 receptor agonists
Connected media – Connected media
